Items where authors include "Xu, X.L."

Article

Ritchlin, C.T. orcid.org/0000-0002-2602-1219, Deodhar, A. orcid.org/0000-0002-2130-1246, Boehncke, W. et al. (8 more authors) (2023) Multidomain Efficacy and Safety of Guselkumab Through 1 Year in Patients With Active Psoriatic Arthritis With and Without Prior Tumor Necrosis Factor Inhibitor Experience: Analysis of the Phase 3, Randomized, Placebo-Controlled DISCOVER-1 Study. ACR Open Rheumatology, 5 (3). pp. 149-164. ISSN 2578-5745

Proceedings Paper

Coates, L., Gossec, L., Contre, C. et al. (8 more authors) (2022) 2127: Guselkumab Provides Continued Improvement in Key Domains of Psoriatic Arthritis Through 2 Years. In: Arthritis & Rheumatology. ACR Convergence 2022, 10-14 Nov 2022, Philadelphia, USA. Wiley , pp. 4214-4216.

Coates, L., Gossec, L., Contre, C. et al. (8 more authors) (2022) POS1017 Guselkumab Provides Continued Improvement In Key Domains Of Psoriatic Arthritis Through 2 Years. In: Annals of the Rheumatic Diseases. EULAR 2022 European Congress of Rheumatology, 01-04 Jun 2022, Copenhagen, Denmark. BMJ , pp. 818-819.

Mease, P.J., Helliwell, P., Gladman, D.D. et al. (10 more authors) (2022) POS1037 Effect Of Guselkumab, A Selective Il-23p19 Inhibitor, On Axial-Related Endpoints In Patients With Active Psa: Results From A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Through 2 Years. In: Annals of the Rheumatic Diseases. EULAR 2022 European Congress of Rheumatology, 01-04 Jun 2022, Copenhagen, Denmark. BMJ , pp. 832-833.